- Home
- GALT vs OXLCP Comparison
GALT vs OXLCP Comparison
Compare GALT & OXLCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- OXLCP
- Stock Information
- Founded
- GALT 2000
- OXLCP N/A
- Country
- GALT United States
- OXLCP United States
- Employees
- GALT N/A
- OXLCP N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- OXLCP Investment Managers
- Sector
- GALT Health Care
- OXLCP Finance
- Exchange
- GALT Nasdaq
- OXLCP Nasdaq
- Market Cap
- GALT 147.8M
- OXLCP N/A
- IPO Year
- GALT N/A
- OXLCP N/A
- Fundamental
- Price
- GALT $1.04
- OXLCP $23.90
- Analyst Decision
- GALT Strong Buy
- OXLCP
- Analyst Count
- GALT 1
- OXLCP 0
- Target Price
- GALT $11.00
- OXLCP N/A
- AVG Volume (30 Days)
- GALT 1.1M
- OXLCP N/A
- Earning Date
- GALT 11-13-2024
- OXLCP N/A
- Dividend Yield
- GALT N/A
- OXLCP N/A
- EPS Growth
- GALT N/A
- OXLCP N/A
- EPS
- GALT N/A
- OXLCP N/A
- Revenue
- GALT N/A
- OXLCP N/A
- Revenue This Year
- GALT N/A
- OXLCP N/A
- Revenue Next Year
- GALT N/A
- OXLCP N/A
- P/E Ratio
- GALT N/A
- OXLCP N/A
- Revenue Growth
- GALT N/A
- OXLCP N/A
- 52 Week Low
- GALT $0.73
- OXLCP N/A
- 52 Week High
- GALT $4.27
- OXLCP N/A
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- OXLCP 37.45
- Support Level
- GALT $1.80
- OXLCP $23.78
- Resistance Level
- GALT $2.36
- OXLCP $24.20
- Average True Range (ATR)
- GALT 0.27
- OXLCP 0.08
- MACD
- GALT -0.08
- OXLCP -0.03
- Stochastic Oscillator
- GALT 15.07
- OXLCP 28.57
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About OXLCP Oxford Lane Capital Corp.
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.